Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form
D-Scholarship @ Pitt Banner and Links to Homepage

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

Gogas, H and Dafni, U and Koon, H and Spyropoulou-Vlachou, M and Metaxas, Y and Buchbinder, E and Pectasides, E and Tsoutsos, D and Polyzos, A and Stratigos, A and Markopoulos, C and Panagiotou, P and Fountzilas, G and Castana, O and Skarlos, P and Atkins, MB and Kirkwood, JM (2010) Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. Journal of Translational Medicine, 8.

[img]
Preview
 PDF
Published Version
Available under License : See the attached license file.
Download (812kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.
Download (1kB)

Abstract

Purpose: Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its acceptance, despite significant durable relapse prevention in a fraction of patients. Predictive biomarkers that would enable selection of patients for therapy would have a large impact upon clinical practice. Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity.Experimental design: 286 melanoma patients and 288 healthy controls were genotyped for six CTLA-4 polymorphisms previously suggested to be important (AG 49, CT 318, CT 60, JO 27, JO30 and JO 31). Specific allele frequencies were compared between the healthy and patient populations, as well as presence or absence of these in relation to recurrence. Alleles related to autoimmune disease were also investigated.Results: No significant differences were found between the distributions of CTLA-4 polymorphisms in the melanoma population compared with healthy controls. Relapse free survival (RFS) and overall survival (OS) did not differ significantly between patients with the alleles represented by these polymorphisms. No correlation between autoimmunity and specific alleles was shown. The six polymorphisms evaluated where strongly associated (Fisher's exact p-values < 0.001 for all associations) and significant linkage disequilibrium among these was indicated.Conclusion: No polymorphisms of CTLA-4 defined by the SNPs studied were correlated with improved RFS, OS, or autoimmunity in this high-risk group of melanoma patients. © 2010 Gogas et al; licensee BioMed Central Ltd.

Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Gogas, H
Dafni, U
Koon, H
Spyropoulou-Vlachou, M
Metaxas, Y
Buchbinder, E
Pectasides, E
Tsoutsos, D
Polyzos, A
Stratigos, A
Markopoulos, C
Panagiotou, P
Fountzilas, G
Castana, O
Skarlos, P
Atkins, MB
Kirkwood, JMkirkwood@pitt.eduKIRKWOOD
Centers: Other Centers, Institutes, Offices, or Units > Hillman Cancer Center
Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute
Date: 11 March 2010
Date Type: Publication
Journal or Publication Title: Journal of Translational Medicine
Volume: 8
DOI or Unique Handle: 10.1186/1479-5876-8-108
Schools and Programs: School of Medicine > Medicine
Refereed: Yes
Date Deposited: 15 Nov 2016 20:15
Last Modified: 04 Feb 2019 15:56
URI: http://d-scholarship.pitt.edu/id/eprint/30215

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

Actions (login required)

View Item View Item